𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association

✍ Scribed by Gary W. Thomas, Hyman B. Muss, Don V. Jackson…

Book ID
120777462
Publisher
Springer
Year
1994
Tongue
English
Weight
401 KB
Volume
35
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cyclophosphamide and 5-fluorou
High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast: A phase III study of the piedmont oncology association (POA)
✍ Patricia J. Zekan; Hyman B. Muss; Robert L. Capizzi; M. Robert Cooper; Robert W. 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 569 KB

Forty-nine patients with advanced carcinoma of the breast who had received no prior chemotherapy were randomized to receive either high-dose cyclophosphamide (C) 1250 mg/M2 intravenously on day 1 and 5-fluorouracil (F) 600 mg/M2 intravenously on days 1 through 5 (CF), or vincristine (V) 1.5 mg/M2, d

A Phase II trial of high dose epirubicin
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 3 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high